EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis

Autores
Michelon, Isabella; Vilbert, Maysa; do Rego Castro, Caio Ernesto; Stecca, Carlos; Dacoregio, Maria Inez; Rizzo, Manglio Miguel; Cláudio Cordeiro de Lima, Vladmir; Cavalcante, Ludimila
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. We systematically searched PubMed, Embase, Cochrane databases, ASCO, and ESMO websites for studies evaluating EGFR-TKI retreatment in advanced/metastatic NSCLC patients. All analyses were performed using R software (v.4.2.2). We included 19 studies (9 CTs and 10 retrospective cohorts) with a total of 886 patients. In a pooled analysis of all patients during retreatment with TKI, median OS was 11.7 months (95% confidence interval [CI] 10.2-13.4 months) and PFS was 3.2 months (95% CI 2.5-3.9 months). ORR was 15% (95% CI 10-21%) and DCR was 61% (95% CI 53-67%). The subanalysis by generation of TKI in the rechallenge period revealed a slightly better ORR for patients on 3rd generation TKI (p = 0.05). Some limitations include the high heterogeneity of some of the analyses and inability to perform certain subanalyses. Our results unequivocally support the benefit of EGFR-TKI rechallenge in EGFR-mutated NSCLC patients progressing on TKI treatment after a TKI-free interval. These findings may be especially valuable in areas where access to novel therapeutic drugs and clinical trials is limited.
Fil: Michelon, Isabella. Universidade Federal de Pelotas; Brasil
Fil: Vilbert, Maysa. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;
Fil: do Rego Castro, Caio Ernesto. Universidade do Brasília; Brasil
Fil: Stecca, Carlos. No especifíca;
Fil: Dacoregio, Maria Inez. Universidade Federal de Pelotas; Brasil
Fil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Cláudio Cordeiro de Lima, Vladmir. Camargo Cancer Center; Brasil
Fil: Cavalcante, Ludimila. University Of Virginia Comprehensive Cancer Center; Estados Unidos
Materia
epidermal growth factor receptor protein tyrosine kinase
non-small-cell lung cancer
rechallenge
tyrosine kinase inhibitors
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/266875
Acceder
id CONICETDig_0eb582baabe3ddd15a1e1feb3b3076e8
oai_identifier_str oai:ri.conicet.gov.ar:11336/266875
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-AnalysisMichelon, IsabellaVilbert, Maysado Rego Castro, Caio ErnestoStecca, CarlosDacoregio, Maria InezRizzo, Manglio MiguelCláudio Cordeiro de Lima, VladmirCavalcante, Ludimilaepidermal growth factor receptor protein tyrosine kinasenon-small-cell lung cancerrechallengetyrosine kinase inhibitorshttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. We systematically searched PubMed, Embase, Cochrane databases, ASCO, and ESMO websites for studies evaluating EGFR-TKI retreatment in advanced/metastatic NSCLC patients. All analyses were performed using R software (v.4.2.2). We included 19 studies (9 CTs and 10 retrospective cohorts) with a total of 886 patients. In a pooled analysis of all patients during retreatment with TKI, median OS was 11.7 months (95% confidence interval [CI] 10.2-13.4 months) and PFS was 3.2 months (95% CI 2.5-3.9 months). ORR was 15% (95% CI 10-21%) and DCR was 61% (95% CI 53-67%). The subanalysis by generation of TKI in the rechallenge period revealed a slightly better ORR for patients on 3rd generation TKI (p = 0.05). Some limitations include the high heterogeneity of some of the analyses and inability to perform certain subanalyses. Our results unequivocally support the benefit of EGFR-TKI rechallenge in EGFR-mutated NSCLC patients progressing on TKI treatment after a TKI-free interval. These findings may be especially valuable in areas where access to novel therapeutic drugs and clinical trials is limited.Fil: Michelon, Isabella. Universidade Federal de Pelotas; BrasilFil: Vilbert, Maysa. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;Fil: do Rego Castro, Caio Ernesto. Universidade do Brasília; BrasilFil: Stecca, Carlos. No especifíca;Fil: Dacoregio, Maria Inez. Universidade Federal de Pelotas; BrasilFil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina. Universidad Austral. Hospital Universitario Austral; ArgentinaFil: Cláudio Cordeiro de Lima, Vladmir. Camargo Cancer Center; BrasilFil: Cavalcante, Ludimila. University Of Virginia Comprehensive Cancer Center; Estados UnidosMDPI2024-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/266875Michelon, Isabella; Vilbert, Maysa; do Rego Castro, Caio Ernesto; Stecca, Carlos; Dacoregio, Maria Inez; et al.; EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis; MDPI; Journal of Personalized Medicine; 14; 7; 7-2024; 1-192075-4426CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2075-4426/14/7/752info:eu-repo/semantics/altIdentifier/doi/10.3390/jpm14070752info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-11-12T09:48:06Zoai:ri.conicet.gov.ar:11336/266875instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-11-12 09:48:06.869CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
title EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
spellingShingle EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
Michelon, Isabella
epidermal growth factor receptor protein tyrosine kinase
non-small-cell lung cancer
rechallenge
tyrosine kinase inhibitors
title_short EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
title_full EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
title_fullStr EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
title_full_unstemmed EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
title_sort EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
dc.creator.none.fl_str_mv Michelon, Isabella
Vilbert, Maysa
do Rego Castro, Caio Ernesto
Stecca, Carlos
Dacoregio, Maria Inez
Rizzo, Manglio Miguel
Cláudio Cordeiro de Lima, Vladmir
Cavalcante, Ludimila
author Michelon, Isabella
author_facet Michelon, Isabella
Vilbert, Maysa
do Rego Castro, Caio Ernesto
Stecca, Carlos
Dacoregio, Maria Inez
Rizzo, Manglio Miguel
Cláudio Cordeiro de Lima, Vladmir
Cavalcante, Ludimila
author_role author
author2 Vilbert, Maysa
do Rego Castro, Caio Ernesto
Stecca, Carlos
Dacoregio, Maria Inez
Rizzo, Manglio Miguel
Cláudio Cordeiro de Lima, Vladmir
Cavalcante, Ludimila
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv epidermal growth factor receptor protein tyrosine kinase
non-small-cell lung cancer
rechallenge
tyrosine kinase inhibitors
topic epidermal growth factor receptor protein tyrosine kinase
non-small-cell lung cancer
rechallenge
tyrosine kinase inhibitors
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. We systematically searched PubMed, Embase, Cochrane databases, ASCO, and ESMO websites for studies evaluating EGFR-TKI retreatment in advanced/metastatic NSCLC patients. All analyses were performed using R software (v.4.2.2). We included 19 studies (9 CTs and 10 retrospective cohorts) with a total of 886 patients. In a pooled analysis of all patients during retreatment with TKI, median OS was 11.7 months (95% confidence interval [CI] 10.2-13.4 months) and PFS was 3.2 months (95% CI 2.5-3.9 months). ORR was 15% (95% CI 10-21%) and DCR was 61% (95% CI 53-67%). The subanalysis by generation of TKI in the rechallenge period revealed a slightly better ORR for patients on 3rd generation TKI (p = 0.05). Some limitations include the high heterogeneity of some of the analyses and inability to perform certain subanalyses. Our results unequivocally support the benefit of EGFR-TKI rechallenge in EGFR-mutated NSCLC patients progressing on TKI treatment after a TKI-free interval. These findings may be especially valuable in areas where access to novel therapeutic drugs and clinical trials is limited.
Fil: Michelon, Isabella. Universidade Federal de Pelotas; Brasil
Fil: Vilbert, Maysa. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;
Fil: do Rego Castro, Caio Ernesto. Universidade do Brasília; Brasil
Fil: Stecca, Carlos. No especifíca;
Fil: Dacoregio, Maria Inez. Universidade Federal de Pelotas; Brasil
Fil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina. Universidad Austral. Hospital Universitario Austral; Argentina
Fil: Cláudio Cordeiro de Lima, Vladmir. Camargo Cancer Center; Brasil
Fil: Cavalcante, Ludimila. University Of Virginia Comprehensive Cancer Center; Estados Unidos
description We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. We systematically searched PubMed, Embase, Cochrane databases, ASCO, and ESMO websites for studies evaluating EGFR-TKI retreatment in advanced/metastatic NSCLC patients. All analyses were performed using R software (v.4.2.2). We included 19 studies (9 CTs and 10 retrospective cohorts) with a total of 886 patients. In a pooled analysis of all patients during retreatment with TKI, median OS was 11.7 months (95% confidence interval [CI] 10.2-13.4 months) and PFS was 3.2 months (95% CI 2.5-3.9 months). ORR was 15% (95% CI 10-21%) and DCR was 61% (95% CI 53-67%). The subanalysis by generation of TKI in the rechallenge period revealed a slightly better ORR for patients on 3rd generation TKI (p = 0.05). Some limitations include the high heterogeneity of some of the analyses and inability to perform certain subanalyses. Our results unequivocally support the benefit of EGFR-TKI rechallenge in EGFR-mutated NSCLC patients progressing on TKI treatment after a TKI-free interval. These findings may be especially valuable in areas where access to novel therapeutic drugs and clinical trials is limited.
publishDate 2024
dc.date.none.fl_str_mv 2024-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/266875
Michelon, Isabella; Vilbert, Maysa; do Rego Castro, Caio Ernesto; Stecca, Carlos; Dacoregio, Maria Inez; et al.; EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis; MDPI; Journal of Personalized Medicine; 14; 7; 7-2024; 1-19
2075-4426
CONICET Digital
CONICET
url http://hdl.handle.net/11336/266875
identifier_str_mv Michelon, Isabella; Vilbert, Maysa; do Rego Castro, Caio Ernesto; Stecca, Carlos; Dacoregio, Maria Inez; et al.; EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis; MDPI; Journal of Personalized Medicine; 14; 7; 7-2024; 1-19
2075-4426
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2075-4426/14/7/752
info:eu-repo/semantics/altIdentifier/doi/10.3390/jpm14070752
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1848597988411179008
score 12.976206

Publicaciones similares